Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds
to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

BACKGROUND:: Cetuximab is a recombinant human/mouse chimeric epidermal growth
factor receptor (EGFR) monoclonal antibody. It was approved by the US Food and Drug …

Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant,
human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the …

The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptors. It
is composed of extracellular domains, including a ligand-binding domain, a hydrophobic …

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and
neck cancer (more than 90%), and all over the world more than a half million people have …

The anti-epidermal-growth-factor-receptor (EGFR) monoclonal antibody cetuximab
specifically binds to the EGFR with high affinity, blocking growth-factor binding, receptor …

Cetuximab is a monoclonal antibody able to inhibit and to degrade the transmembrane
receptor Her-1, also known as epidermal growth factor receptor (EGFR). The inhibition of …

Cetuximab (Erbitux, IMC‐C225) is a monoclonal antibody targeted to the epidermal growth
factor receptor (EGFR). To clarify the mode of antitumor action of cetuximab, we examined …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …